Clinical Trial Update: Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

Phase 1 study of ibrutinib in combination with lenalidomide and dexamethasone for relapsed/refractory multiple myeloma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• IMBRUVICA (IBRUTINIB)
• Revlimid (lenalidomide)

Snippet

Sponsor: Alliance Foundation Trials, LLC. | Conditions: Refractory Multiple Myeloma, Multiple Myeloma in Relapse | Phase 1 | Status: COMPLETED | Results posted: 2026-01-06